038290:KOSDAQ
Macrogen Inc
11 490,00 ₩
arrow_downward
-1,29%(-150,00) 1K
20-noy, 15:30:30 (GMT+9) · KRW
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto038290 tikeri uchun statistika yaratilmoqda...
Ochish
11 500 ₩
Yuqori
11 600 ₩
Past
11 220 ₩
Bozor kapitali
124,57 mlrd
Oʻrtacha hajm
13,67 ming
Hajmi
7,97 ming
Dividend
4,35%
Choraklik dividendlar
125 ₩
Eks-dividend sanasi
29-dek, 2026
P/E koeffitsiyenti
12,05
52 haftalik eng yuqori
20 900 ₩
52 haftalik eng past
10 440 ₩
Aksiya boʻyicha daromad
953 ₩
Muomaladagi aksiyalar
10,84 mln
Xodimlar soni
473
Ochish
11 500 ₩
Yuqori
11 600 ₩
Past
11 220 ₩
Bozor kapitali
124,57 mlrd
Oʻrtacha hajm
13,67 ming
Hajmi
7,97 ming
Dividend
4,35%
Choraklik dividendlar
125 ₩
Eks-dividend sanasi
29-dek, 2026
P/E koeffitsiyenti
12,05
52 haftalik eng yuqori
20 900 ₩
52 haftalik eng past
10 440 ₩
Aksiya boʻyicha daromad
953 ₩
Muomaladagi aksiyalar
10,84 mln
Xodimlar soni
473
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Yahoo Finance
·
3 soat oldin
Stock market today: Dow, S&P 500, Nasdaq futures continue to sell-off after Anthropic IPO fails to quell AI worries
CNBC
·
34 daqiqa oldin
S&P 500 and Dow enter correction, Nasdaq wipes out 2026 gain as Anthropic leads AI sell-off: Live updates
Seeking Alpha
·
1 soat oldin
S&P 500 is near a bottom, but breadth still shows final low is not there yet – BTIG’s Krinsky (SP500:)
Profil
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Macrogen Inc haqida
CEOSeo Jeong-seon
Xodimlar soni473
Asos solingan5-iyn, 1997
Bosh ofislar-
SektorHealth Care
Soha-
Veb-saytmacrogen.com